

# David E Lanfear

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/703846/publications.pdf>

Version: 2024-02-01

159  
papers

4,984  
citations

87888

38  
h-index

110387

64  
g-index

175  
all docs

175  
docs citations

175  
times ranked

6980  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival Association of Angiotensin Inhibitors in Heart Failure With Reduced Ejection Fraction: Comparisons Using Self-Identified Race and Genomic Ancestry. <i>Journal of Cardiac Failure</i> , 2022, 28, 215-225.	1.7	0
2	The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. <i>Nature Medicine</i> , 2022, 28, 809-813.	30.7	107
3	Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 765-774.	1.7	5
4	Polygenic Score For Beta-blocker Survival Benefit In Heart Failure With Preserved Ejection Fraction Patients. <i>Journal of Cardiac Failure</i> , 2022, 28, S79.	1.7	0
5	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. <i>Circulation</i> , 2022, 146, 808-818.	1.6	33
6	Mapping the 17q12â€“21.1 Locus for Variants Associated with Early-Onset Asthma in African Americans. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 424-436.	5.6	16
7	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	27.0	381
8	Novel Trial Design: CHIEF-HF. <i>Circulation: Heart Failure</i> , 2021, 14, e007767.	3.9	23
9	Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 226-236.	4.1	26
10	Functional dynamic genetic effects on gene regulation are specific to particular cell types and environmental conditions. <i>ELife</i> , 2021, 10, .	6.0	41
11	Plasma Proteomic Profile Predicts Survival in Heart Failure With Reduced Ejection Fraction. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003140.	3.6	11
12	BNP and Precision Medicine. <i>JACC Basic To Translational Science</i> , 2021, 6, 505-506.	4.1	2
13	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.	2.8	73
14	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 314.	7.4	68
15	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	3.1	11
16	Predicting death from COVID-19 using pre-existing conditions: implications for vaccination triage. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001016.	3.0	1
17	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020, 220, 41-50.	2.7	22
18	Outcomes based on blood pressure in patients on continuous flow left ventricular assist device support: An Interagency Registry for Mechanically Assisted Circulatory Support analysis. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 441-453.	0.6	17

#	ARTICLE	IF	CITATIONS
19	Impact of Socioeconomic Factors on Patient Desire for Early LVAD Therapy Prior to Inotrope Dependence. <i>Journal of Cardiac Failure</i> , 2020, 26, 316-323.	1.7	9
20	Risk Prediction in Transition: MAGGIC Score Performance at Discharge and Incremental Utility of Natriuretic Peptides. <i>Journal of Cardiac Failure</i> , 2020, 26, 52-60.	1.7	10
21	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <sc>GALACTICâ€HF</sc> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	7.1	47
22	Biomarker Guided Therapy For Heart Failure With Mid-Range EF. <i>Journal of Cardiac Failure</i> , 2020, 26, S37.	1.7	0
23	Polygenic Score for Î²-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e007012.	3.9	18
24	Cause of Death in Patients With Acuteâ€Heartâ€Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	4.1	12
25	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic. <i>Circulation: Heart Failure</i> , 2020, 13, e007456.	3.9	6
26	Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience. <i>Clinical Transplantation</i> , 2020, 34, e14091.	1.6	13
27	A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction. <i>Cardiology and Therapy</i> , 2020, 9, 561-568.	2.6	0
28	National Landscape of Hospitalizations in Patients with Left Ventricular Assist Device. Insights from the National Readmission Database 2010â€2015. <i>ASAIO Journal</i> , 2020, 66, 1087-1094.	1.6	5
29	Suppression tumorigenicity 2 (ST2) turbidimetric immunoassay compared to enzyme-linked immunosorbent assay in predicting survival in heart failure patients with reduced ejection fraction. <i>Clinica Chimica Acta</i> , 2020, 510, 767-771.	1.1	6
30	Effectiveness of beta blockers in patients with and without a history of myocardial infarction. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1161-1168.	1.9	3
31	Omics phenotyping in heart failure: the next frontier. <i>European Heart Journal</i> , 2020, 41, 3477-3484.	2.2	48
32	Asthma and its relationship to mitochondrial copy number: Results from the Asthma Translational Genomics Collaborative (ATGC) of the Trans-Omics for Precision Medicine (TOPMed) program. <i>PLoS ONE</i> , 2020, 15, e0242364.	2.5	16
33	Abstract 16003: Genetic Variation Associated With Favorable Exercise Response in Patients With Systolic Heart Failure: A Hf-action Trial Substudy. <i>Circulation</i> , 2020, 142, .	1.6	0
34	Abstract 15985: Comparison of Survival Benefit From Angiotensin Inhibitors in Patients With Heart Failure and Reduced Ejection Fraction by Race and Genomic Ancestry. <i>Circulation</i> , 2020, 142, .	1.6	0
35	Performance of the Meta-Analysis Global Group in Chronic Heart Failure Score in Black Patients Compared With Whites. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004714.	2.2	6
36	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1463-1476.	1.6	279

#	ARTICLE	IF	CITATIONS
37	Genetics of heart rate in heart failure patients (GenHRate). <i>Human Genomics</i> , 2019, 13, 22.	2.9	9
38	Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 806-816.	0.6	61
39	Liquid Biopsy and eHealth in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2206-2208.	2.8	5
40	Association of Regulatory Genetic Variants for Protein Kinase C $\beta$ with Mortality and Drug Efficacy in Patients with Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 693-700.	2.6	0
41	Single-Cell RNA Sequencing of the Cardiovascular System: New Looks for Old Diseases. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 173.	2.4	47
42	Integrative approach identifies corticosteroid response variant in diverse populations with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1791-1802.	2.9	33
43	Pulmonary Function Testing and Outcomes after Left Ventricular Assist Device Implantation. <i>Heart Surgery Forum</i> , 2019, 22, E202-E206.	0.5	6
44	Cardiopulmonary Exercise Measures of Men and Women with HFrEF Differ in Their Relationship to Prognosis: The Henry Ford Hospital Cardiopulmonary Exercise Testing (FIT-CPX) Project. <i>Journal of Cardiac Failure</i> , 2018, 24, 227-233.	1.7	8
45	When the VEST Does Not Fit. <i>Circulation: Heart Failure</i> , 2018, 11, e005116.	3.9	2
46	Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients. <i>European Journal of Heart Failure</i> , 2018, 20, 67-75.	7.1	63
47	Challenges with Percent Predicted Maximal $\dot{V}E^{TM}O_2$ in Patients with Heart Failure. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 204-210.	0.4	5
48	Improving Mitochondrial Function Improves the Plasma Metabolite Profile in Experimental Heart Failure. <i>Journal of Cardiac Failure</i> , 2018, 24, S79-S80.	1.7	0
49	Race and Beta-blocker Survival Benefit in Patients With Heart Failure: An Investigation of Self-reported Race and Proportion of African Genetic Ancestry. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	15
50	Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 319-328.	2.6	43
51	Embracing the Long Road to Precision Medicine. <i>Circulation: Heart Failure</i> , 2018, 11, e005089.	3.9	3
52	Practical data handling pipeline improves performance of qPCR-based circulating miRNA measurements. <i>Rna</i> , 2017, 23, 811-821.	3.5	58
53	Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	29
54	Prognostic Value of Serial N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2017, 120, 181-185.	1.6	16

#	ARTICLE	IF	CITATIONS
55	Pharmacogenomics of the Natriuretic Peptide System in Heart Failure. <i>Current Heart Failure Reports</i> , 2017, 14, 536-542.	3.3	17
56	Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2017, 5, 823-832.	4.1	63
57	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2016, 23, 922-931.	1.8	10
58	Merging Electronic Health Record Data and Genomics for Cardiovascular Research. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 193-202.	5.1	20
59	Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1364-1369.e2.	2.9	25
60	Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9-Year Experience. <i>Annals of Thoracic Surgery</i> , 2016, 102, 1266-1273.	1.3	18
61	Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 448-467.	5.1	64
62	Predicting Mortality at Discharge Following Hospitalization for Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, S21-S22.	1.7	0
63	Cognitive Functioning and Post-LVAD Outcomes: Influence of Comorbidities and Specific Cognitive Domains. <i>Journal of Cardiac Failure</i> , 2016, 22, S124.	1.7	1
64	Practical Pharmacogenomic Approaches to Heart Failure Therapeutics. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 60.	0.9	7
65	Performance of MAGGIC Score in African Americans Compared to Whites. <i>Journal of Cardiac Failure</i> , 2016, 22, S101.	1.7	0
66	Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e468-e495.	1.6	203
67	Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?. <i>Journal of the American Heart Association</i> , 2016, 5, e003440.	3.7	3
68	Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 20-26.	2.0	2
69	Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford Hospital CardioPulmonary EXercise Testing (FIT-CPX) project. <i>American Heart Journal</i> , 2016, 174, 167-172.	2.7	78
70	Effect of Preoperative Albumin Levels on Outcomes in Patients Undergoing Left Ventricular Device Implantation. <i>ASAIO Journal</i> , 2015, 61, 734-737.	1.6	21
71	Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 545-553.	2.4	4
72	Basic Concepts and Potential Applications of Genetics and Genomics for Cardiovascular and Stroke Clinicians. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 216-242.	5.1	41

#	ARTICLE	IF	CITATIONS
73	Comprehensive Analysis of Cardiopulmonary Exercise Testing and Mortality in Patients With Systolic Heart Failure: The Henry Ford Hospital Cardiopulmonary Exercise Testing (FIT-CPX) Project. <i>Journal of Cardiac Failure</i> , 2015, 21, 710-718.	1.7	15
74	Beta Blocker Survival Benefit in Heart Failure is Associated with ADRB1 Ser49Gly Genotype. <i>Journal of Cardiac Failure</i> , 2015, 21, S50.	1.7	4
75	Metabolomic Patterns in Heart Failure Patients Vary Across Demographic and Clinical Factors. <i>Journal of Cardiac Failure</i> , 2015, 21, S88-S89.	1.7	0
76	Future Translational Applications From the Contemporary Genomics Era. <i>Circulation</i> , 2015, 131, 1715-1736.	1.6	38
77	Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. <i>Heart Failure Reviews</i> , 2015, 20, 573-578.	3.9	14
78	Waiting to Inhale – Milrinone. <i>Journal of Cardiac Failure</i> , 2015, 21, 798-799.	1.7	1
79	Association of Antidiabetic Medications Targeting the Glucagon-Like Peptide 1 Pathway and Heart Failure Events in Patients With Diabetes. <i>Journal of Cardiac Failure</i> , 2015, 21, 2-8.	1.7	33
80	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions – A Consensus Document from the SAEM/HFSA Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2015, 22, 94-112.	1.8	41
81	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2015, 21, 27-43.	1.7	73
82	Joint Impact of Clinical and Behavioral Variables on the Risk of Unplanned Readmission and Death after a Heart Failure Hospitalization. <i>PLoS ONE</i> , 2015, 10, e0129553.	2.5	20
83	Short and long term outcomes of 200 patients supported by continuous-flow left ventricular assist devices. <i>World Journal of Cardiology</i> , 2015, 7, 792.	1.5	46
84	Abstract 16395: Comparing Cardiopulmonary Exercise Measures of Men and Women With HFrEF and Their Relationship to Prognosis: The Henry Ford Hospital Cardiopulmonary Exercise Testing (FIT-CPET) Project. <i>Circulation</i> , 2015, 132, .	1.6	0
85	Dosing of Vancomycin in Patients with Continuous-Flow Left Ventricular Assist Devices: A Clinical Pharmacokinetic Analysis. <i>International Journal of Artificial Organs</i> , 2014, 37, 270-274.	1.4	7
86	Relationship of Tricuspid Repair at the Time of Left Ventricular Assist Device Implantation and Survival. <i>International Journal of Artificial Organs</i> , 2014, 37, 834-838.	1.4	25
87	Assessing the Potential of E-mail for Communicating Drug Therapy Recommendations to Physicians in Patients With Heart Failure and Ventricular-Assist Devices. <i>Journal of Pharmacy Practice</i> , 2014, 27, 478-480.	1.0	4
88	Cardiac Rehabilitation Improves Functional Capacity and Patient-Reported Health Status in Patients With Continuous-Flow Left Ventricular Assist Devices. <i>JACC: Heart Failure</i> , 2014, 2, 653-659.	4.1	121
89	Stroke While on Long-Term Left Ventricular Assist Device Support. <i>ASAIO Journal</i> , 2014, 60, 284-289.	1.6	86
90	Pharmacogenomics in Heart Failure. <i>Cardiology in Review</i> , 2014, 22, 193-198.	1.4	14

#	ARTICLE	IF	CITATIONS
91	Epidemiology and Outcomes Associated With Anemia During Long-Term Support With Continuous-Flow Left Ventricular Assist Devices. <i>Journal of Cardiac Failure</i> , 2014, 20, 387-391.	1.7	17
92	Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel-Treated Patients After Acute Myocardial Infarction. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 277-286.	5.1	50
93	Left Ventricular Assist Devices and Changes in Leukocyte Count. <i>Journal of Cardiac Failure</i> , 2014, 20, S33.	1.7	0
94	Genetic and Nongenetic Factors Influencing Pharmacokinetics of B-Type Natriuretic Peptide. <i>Journal of Cardiac Failure</i> , 2014, 20, 662-668.	1.7	13
95	Gap between clinical guidelines and practice: The case of aldosterone-antagonists in patients with myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 172, e151-e153.	1.7	3
96	Differing Effects of Metformin on Glycemic Control by Race-Ethnicity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3160-3168.	3.6	68
97	Type of $\beta^2$ -blocker use among patients with versus without diabetes after myocardial infarction. <i>American Heart Journal</i> , 2014, 168, 273-279.e1.	2.7	14
98	Patient Characteristics and Participation in a Genetic Study. <i>Journal of Investigative Medicine</i> , 2014, 62, 26-32.	1.6	7
99	Abstract 18836: Differences in Cardiopulmonary Exercise Test Data and Prognosis in Black and White Men with Heart Failure: the Henry Ford Hospital CardioPulmonary EXercise Testing (FIT-CPX) Project. <i>Circulation</i> , 2014, 130, .	1.6	0
100	Abstract 14681: Uber Analysis of Cardiopulmonary Exercise Test Variables and Mortality in Patients with Heart Failure: the Henry Ford Hospital CardioPulmonary EXercise Testing (FIT-CPX) Project. <i>Circulation</i> , 2014, 130, .	1.6	0
101	Abstract 17154: Cardiopulmonary Exercise Testing and Prognosis in HFpEF: the Henry Ford Hospital CardioPulmonary EXercise Testing (FIT-CPX) Project. <i>Circulation</i> , 2014, 130, .	1.6	0
102	Abstract 14036: An Algorithm to Guide Prognosis Based on the Combination of Peak $VO_2$ and $V_E$ -VCO <sub>2</sub> slope in Patients with HFrEF: The Henry Ford Hospital CardioPulmonary EXercise Testing (FIT-CPX) Project. <i>Circulation</i> , 2014, 130, .	1.6	0
103	Policies and events affecting prescription opioid use for non-cancer pain among an insured patient population. <i>Pain Physician</i> , 2014, 17, 205-16.	0.4	9
104	Ventricular Assist Devices: Is Destination Therapy a Viable Alternative in the Non-Transplant Candidate?. <i>Current Heart Failure Reports</i> , 2013, 10, 101-107.	3.3	17
105	Association of Genetic Variation with Gene Expression and Protein Abundance within the Natriuretic Peptide Pathway. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 826-833.	2.4	6
106	Comparison of Beta-Blocker Effectiveness in Heart Failure Patients With Preserved Ejection Fraction Versus Those With Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2013, 19, 73-79.	1.7	22
107	Impact of continuous-flow left ventricular assist device support on right ventricular function. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 398-403.	0.6	111
108	Effect of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality. <i>American Journal of Cardiology</i> , 2013, 111, 532-539.	1.6	15

#	ARTICLE	IF	CITATIONS
109	Incidence and Associated Variable Cost of Hospital Readmission during Long-Term Continuous Flow Left Ventricular Assist Device (CF-LVAD) Implantation. <i>Journal of Cardiac Failure</i> , 2013, 19, S59.	1.7	0
110	Failure to reassess ejection fraction after acute myocardial infarction in potential implantable cardioverter/defibrillator candidates: Insights from the Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status (TRIUMPH) registry. <i>American Heart Journal</i> , 2013, 166, 737-743.	2.7	15
111	Patients with low compared with high body mass index gain more weight after implantation of a continuous-flow left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 31-35.	0.6	40
112	Acute Intravenous Infusion of an Adenosine Regulating Agent Improves Left Ventricular Function in Dogs with Advanced Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 489-498.	2.6	2
113	High Rates of False-Positive Hepatitis C Antibody Tests Can Occur After Left Ventricular Assist Device Implantation. <i>ASAIO Journal</i> , 2013, 59, 660-661.	1.6	16
114	Insulin Resistance Is Associated With Significant Clinical Atherosclerosis in Nondiabetic Patients With Acute Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2245-2251.	2.4	31
115	Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2013, 6, 47-52.	3.9	61
116	Left Ventricular Reverse Remodeling With a Continuous Flow Left Ventricular Assist Device Measured by Left Ventricular End-Diastolic Dimensions and Severity of Mitral Regurgitation. <i>ASAIO Journal</i> , 2012, 58, 574-577.	1.6	62
117	Association of $\beta$ -Blocker Exposure With Outcomes in Heart Failure Differs Between African American and White Patients. <i>Circulation: Heart Failure</i> , 2012, 5, 202-208.	3.9	35
118	Label Space Transfer Learning. , 2012, , .		1
119	Comparison of renal predictors for in-hospital and postdischarge mortality after hospitalized heart failure. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 246-253.	1.5	17
120	Management of Aortic Valve Insufficiency in Patients Supported By Long-Term Continuous Flow Left Ventricular Assist Devices. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1710-1712.	1.3	20
121	Extremes of body mass index do not impact mid-term survival after continuous-flow left ventricular assist device implantation. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 167-172.	0.6	51
122	Gastrointestinal bleeding with the HeartMate II left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 715-718.	0.6	146
123	Non-cardiac surgery in patients on long-term left ventricular assist device support. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 757-763.	0.6	77
124	Adrenergic-Pathway Gene Variants Influence Beta-Blocker-Related Outcomes After Acute Coronary Syndrome in a Race-Specific Manner. <i>Journal of the American College of Cardiology</i> , 2012, 60, 898-907.	2.8	35
125	Assessment of the Heart Failure Pharmacotherapy of Patients with Continuous Flow Left-Ventricular Assist Devices. <i>International Journal of Artificial Organs</i> , 2012, 35, 177-179.	1.4	7
126	Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges. <i>Current Heart Failure Reports</i> , 2012, 9, 23-32.	3.3	32



#	ARTICLE	IF	CITATIONS
127	Factors influencing patient willingness to participate in genetic research after a myocardial infarction. <i>Genome Medicine</i> , 2011, 3, 39.	8.2	21
128	Immediate Post-Transplant Hyperglycemia and the Risk of Heart Allograft Rejection. <i>Journal of Cardiac Failure</i> , 2011, 17, S50.	1.7	0
129	Natriuretic Peptide Receptor 3 Genotype Is Associated with Altered Pharmacokinetics during Nesiritide Infusion. <i>Journal of Cardiac Failure</i> , 2011, 17, S62.	1.7	1
130	Relation of Worsened Renal Function During Hospitalization for Heart Failure to Long-Term Outcomes and Rehospitalization. <i>American Journal of Cardiology</i> , 2011, 107, 74-78.	1.6	32
131	ACCF/AHA/HFSA 2011 Survey Results: Current Staffing Profile of Heart Failure Programs, Including Programs That Perform Heart Transplant and Mechanical Circulatory Support Device Implantation. <i>Circulation: Heart Failure</i> , 2011, 4, 378-387.	3.9	21
132	Abstract P234: Discharge Medication Status Compares Poorly with Claims-Based Outpatient Medication Exposure Estimates. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, .	2.2	2
133	Relationship of Loop Diuretic Dosing and Acute Changes in Renal Function during Hospitalization for Heart Failure. <i>Journal of Clinical &amp; Experimental Cardiology</i> , 2011, 02, .	0.0	8
134	Genome-wide approach to identify novel candidate genes for beta blocker response in heart failure using an experimental model. <i>Discovery Medicine</i> , 2011, 11, 359-66.	0.5	8
135	Genetic variation in the natriuretic peptide system and heart failure. <i>Heart Failure Reviews</i> , 2010, 15, 219-228.	3.9	39
136	Impact of a continuous flow left ventricular assist device on right ventricular function. <i>Journal of the American College of Surgeons</i> , 2010, 211, S31-S32.	0.5	0
137	A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 225-231.e4.	2.9	62
138	Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1131-1138.	2.9	36
139	B-Type Natriuretic Peptide Pathway Genetic Sequence Variants and Correlation to Gene Expression. <i>Journal of Cardiac Failure</i> , 2010, 16, S40-S41.	1.7	0
140	Interaction of Gender and Change in B-Type Natriuretic Peptide Levels With Blood Pressure Lowering during Nesiritide Infusion. <i>Journal of Cardiac Failure</i> , 2010, 16, S75.	1.7	0
141	Progress toward genetic tailoring of heart failure therapy. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 294-304.	2.8	3
142	Effect of "Energy Drink" Consumption on Hemodynamic and Electrocardiographic Parameters in Healthy Young Adults. <i>Annals of Pharmacotherapy</i> , 2009, 43, 596-602.	1.9	110
143	Comparing methods for identifying patients with heart failure using electronic data sources. <i>BMC Health Services Research</i> , 2009, 9, 237.	2.2	28
144	Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 437-447.	1.9	45

#	ARTICLE	IF	CITATIONS
145	Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure. <i>Journal of Translational Medicine</i> , 2009, 7, 67.	4.4	20
146	Relationship between recent short-acting $\beta_2$ -agonist use and subsequent asthma exacerbations. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 101, 482-487.	1.0	46
147	Myoglobin and troponin I elevation predict 5-year mortality in patients with undifferentiated chest pain in the emergency department. <i>American Heart Journal</i> , 2008, 156, 939-945.	2.7	9
148	Safety and Tolerability of Angiotensin-Converting Enzyme Inhibitor Versus the Combination of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Patients With Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cardiac Failure</i> , 2008, 14, 181-188.	1.7	115
149	Race-Ethnic Differences in Factors Associated with Inhaled Steroid Adherence among Adults with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1194-1201.	5.6	59
150	Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. <i>American Heart Journal</i> , 2007, 154, 561-566.	2.7	34
151	Patients with asthma who do not fill their inhaled corticosteroids: A study of primary nonadherence. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 1153-1159.	2.9	148
152	Genetic Variation in the B-Type Natriuretic Peptide Pathway Affects BNP Levels. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 55-62.	2.6	38
153	Pharmacogenetics: using DNA to optimize drug therapy. <i>American Family Physician</i> , 2007, 76, 1179-82.	0.1	20
154	$\beta_2$ -Adrenergic Receptor Genotype Predicts Survival. <i>Journal of Cardiovascular Nursing</i> , 2006, 21, 474-477.	1.1	4
155	Natriuretic peptide receptor 3 genotype modulates the relationship between B-type natriuretic peptide and left ventricular end-diastolic pressure. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 765-771.	0.2	4
156	$\beta_2$ -Adrenergic Receptor Genotype and Survival Among Patients Receiving $\beta_2$ -Blocker Therapy After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1526.	7.4	177
157	Frequency of compound genotypes associated with $\beta_2$ -blocker efficacy in congestive heart failure. <i>Pharmacogenomics</i> , 2004, 5, 553-558.	1.3	9
158	Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. <i>Journal of the American College of Cardiology</i> , 2004, 44, 165-167.	2.8	36
159	Sequence variants of natriuretic peptide receptor C are common and their frequency differs between African Americans and European Americans. <i>Journal of Cardiac Failure</i> , 2004, 10, S59.	1.7	4